Sheela Tejwani, MD, presents the case of an 83-year-old man with mCSPC, and shares her first impressions as compared to her typical patients.
An 83-Year-Old Man with Biochemically Recurrent Metastatic Castration-Sensitive Prostate Cancer
Dr Tejwani lists the frontline treatment options currently available for mCSPC and reviews the chosen treatment regimen in the presented patient case.
An expert oncologist describes her approaches to treating patients with castration-sensitive prostate cancer and low-volume metastatic disease.
An expert oncologist describes her approaches to treating patients with castration-sensitive prostate cancer and low-volume metastatic disease.
Sheela Tejwani, MD, highlights some exciting recent trial data and shares clinical pearls for community oncologists treating mCSPC.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5
